港股异动 | 和铂医药-B(02142)高开近15% 与阿斯利康达成全球战略合作 溢价发行股份获资1.05亿美元

智通财经
24 Mar

智通财经APP获悉,和铂医药-B(02142)高开近15%,截至发稿,涨14.94%,报9港元,成交额1431.9万港元。

消息面上,和铂医药公布,向全球生物制药公司AstraZeneca发行7627.17万股新股,每股作价10.74港元,较3月21日收报溢价37.2%,所得总额1.05亿美元,将用作研发、营运及一般营运资金需求。完成后,AstraZeneca将持有公司股本9.15%。同时,双方订立全球战略合作协议,共同研发针对免疫性疾病、肿瘤及其他多种疾病的新一代多特异性抗体,据此,AstraZeneca将获得两个临床前免疫研发项目的授权许可选择权,并将进一步提名更多靶点,由公司开发下一代多特异性抗体疗法。AstraZeneca将拥有授权许可该等项目的选择权以推进这些项目进入临床开发阶段。

和铂医药将获得总计1.75亿美元的首付款、近期里程碑付款和额外新增项目的选择权行使费,以及最高达44亿美元的研发及商业里程碑付款,外加基于未来产品净销售额的分级特许权使用费。此外,双方还可选择在未来五年内将更多项目纳入合作范围,并可在双方同意的情况下将协议期限再延长五年。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10